Tactile Systems Technology — Third Quarter 2026 Earnings Summary

Tactile Systems Technology, Inc. reported third-quarter 2026 total revenue of $91.9 million, representing a 7% year-over-year increase driven by a 13% rise in lymphedema product sales. Net income for the quarter decreased to $7.2 million, or $0.31 per diluted share, from $8.2 million in the same period last year, while adjusted EBITDA remained relatively flat at $14.3 million. The company expanded its gross margin to 77% and received FDA clearance for an updated LymphaTech 3D Scanner indication. Management maintains its full-year 2026 revenue guidance between $360 million and $366 million and raised its adjusted EBITDA outlook to a range of $50 million to $52 million.